Literature DB >> 12891114

Ruptured thoracoabdominal aortic aneurysm treatment in the United States: 1988 to 1998.

John A Cowan1, Justin B Dimick, Reid M Wainess, Peter K Henke, James C Stanley, Gilbert R Upchurch.   

Abstract

OBJECTIVE: Thoracoabdominal aortic aneurysm (TAAA) rupture usually results in death. The outcome remains poor for patients who reach the operating room. The objective of this investigation was to define contemporary surgical experience with ruptured TAAA in the United States. Patients and methods Clinical data derived from the Nationwide Inpatient Sample on patients who underwent repair of a ruptured TAAA from 1988 to 1998 were analyzed. Age, sex, race, nature of admission, comorbid conditions, and provider volume were abstracted from the database. In-hospital mortality, postoperative complications, and length of stay were the principal outcome measures.
RESULTS: Three hundred twenty-one patients were identified for the study. Mean age was 71.5 years; men outnumbered women (63% vs 37%). Crude overall surgical mortality was 53.8% and did not improve over time. Operative mortality was most likely (51%) to occur within the first 24 hours postoperatively. Median length of stay for surviving patients was 16 days. Renal failure (28%) and cardiac complications (18%) were the most common complications. In a logistic regression model, age greater than 77 years was predictive of death (odds ratio [OR], 2.5; P =.005), and nonwhite race appeared protective (OR, 0.53; P =.013).
CONCLUSIONS: Mortality after surgical treatment of ruptured TAAA is high. Surviving patients experience many postoperative complications and have lengthy hospital stays. Given the lack of significant improvement in contemporary surgical practice, new techniques of repair deserve the attention of clinicians.

Entities:  

Mesh:

Year:  2003        PMID: 12891114     DOI: 10.1016/s0741-5214(03)00227-1

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  Patient selection for open thoracoabdominal aneurysm repair.

Authors:  Marc A A M Schepens; Filip G J Van den Brande
Journal:  Ann Cardiothorac Surg       Date:  2012-09

2.  Survival after open versus endovascular thoracic aortic aneurysm repair in an observational study of the Medicare population.

Authors:  Philip P Goodney; Lori Travis; F Lee Lucas; Mark F Fillinger; David C Goodman; Jack L Cronenwett; David H Stone
Journal:  Circulation       Date:  2011-11-21       Impact factor: 29.690

3.  Trends in utilization of adrenalectomy in the United States: have indications changed?

Authors:  Brian D Saunders; Reid M Wainess; Justin B Dimick; Gilbert R Upchurch; Gerard M Doherty; Paul G Gauger
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

4.  Outcomes of surgeon-modified fenestrated-branched endograft repair for acute aortic pathology.

Authors:  Salvatore T Scali; Dan Neal; Vida Sollanek; Tomas Martin; Julie Sablik; Thomas S Huber; Adam W Beck
Journal:  J Vasc Surg       Date:  2015-08-05       Impact factor: 4.268

5.  Treatment of acute visceral aortic pathology with fenestrated/branched endovascular repair in high-surgical-risk patients.

Authors:  Salvatore T Scali; Alyson Waterman; Robert J Feezor; Tomas D Martin; Philip J Hess; Thomas S Huber; Adam W Beck
Journal:  J Vasc Surg       Date:  2013-05-21       Impact factor: 4.268

6.  Single Center Experience with Endovascular Repair of Acute Thoracoabdominal Aortic Aneurysms.

Authors:  Athanasios Katsargyris; Pablo Marques de Marino; Balazs Botos; Sebastian Nagel; Anas Ibraheem; Eric L G Verhoeven
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-08       Impact factor: 2.740

Review 7.  Using risk models to improve patient selection for high-risk vascular surgery.

Authors:  Philip P Goodney
Journal:  Scientifica (Cairo)       Date:  2012-12-13

8.  Endovascular stent graft repair of aortogastric fistula caused by peptic ulcer after esophagectomy: A case report.

Authors:  Xiao-Qing Wei; Lei Song; Xue-Song Zhang; Kui-Yang Wang; Jie Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.